Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06673069 · ClinicalTrials.gov registry record · Phase 1
Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)
A Phase 1 study, sponsored by Ionis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT06673069 is a Phase 1 study that was terminated before completion, run by Ionis Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT06673069, a Phase 1 study, was terminated before completion, sponsored by Ionis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.
Interventions
- DRUG ION269
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-12-20 |
| Est. Completion | 2025-12-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06673069
The ClinicalTrials.gov registry entry for NCT06673069 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ION269 is the first listed.
NCT06673069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06673069 about?
NCT06673069 is a clinical study titled "Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)". The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.
What is the current status of trial NCT06673069?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2024-12-20. Estimated completion is 2025-12-03.
What interventions are being tested in trial NCT06673069?
The interventions under investigation include: ION269 (DRUG).
Who is sponsoring clinical trial NCT06673069?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.